While GW Pharmaceuticals did not have any active sites or Canadian patients, the Ontario Rett Syndrome Assocation (O.R.S.A.) was actively supporting them to establish a Canadian location.  While this news is disappointing, it is understandable given the current COIVD-19 implications across the world.  O.R.S.A. remains committed to bringing Rett syndrome Clinical Trials to Canada to ensure that individuals with Rett syndrome are enabled to achieve their fullest potential and enjoy the highest quality of life within their community.